```
125:238671 CA
AN
     T-lymphocyte gene CD28 expression inhibition by oligonucleotides
TΙ
     containing guanine quartet and treatment of immune system-mediated
     diseases
     Tam, Robert C.
IN
     Icn Pharmaceuticals, Inc., USA
PA
SO
     PCT Int. Appl., 77 pp.
     CODEN: PIXXD2
DT
     Patent
     English
LΑ
ΙC
     ICM A61K048-00
CC
     1-7 (Pharmacology)
     Section cross-reference(s): 3, 14, 15
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                           APPLICATION NO. DATE
     _____
                     ----
                                           -----
     WO 9624380
                      A1 19960815
                                           WO 1996-US1507 19960205
PΙ
         W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG,
             KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL,
             RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
                                          US 1995-529878
     US 5932556
                      Α
                            19990803
                                                            19950917
     CA 2211621
                            19960815
                                           CA 1996-2211621 19960205
                      AA
    AU 9652958
                      A1
                            19960827
                                           AU 1996-52958
                                                             19960205
    AU 703139
                            19990318
                      В2
     CN 1181021
                            19980506
                                           CN 1996-193197
                                                            19960205
                      A
                      19950209
PRAI US 1995-387041
     US 1995-529878
                      19950917
    WO 1996-US1507
                     19960205
    Oligomers are provided which are capable of reducing CD28 gene in a T
AΒ
     cell. In addn. to specific sequences, the invention includes a class of
     oligomers having at least two sequences of GGGG sepd. by 3 to 5 bases.
    Targets include CD28 gene, 5' untranslated regions and initiation codon, and their resp. transcripts. Methods include use of the oligomers to
    moderate the pathogenic effects on the immune system in immune
     system-mediated diseases including graft vs. host disease, septic shock
     syndrome, viral diseases, psoriasis, Type I (insulin-dependent) diabetes
     mellitus, thyroiditis, sarcoidosis, multiple sclerosis, autoimmune
     uveitis, rheumatoid arthritis, systemic lupus erythematosus and
     inflammatory bowel disease.
     quanine quartet oligonucleotide inhibition gene CD28; antigen CD28 gene
     expression inhibition oligonucleotide; immune disease CD28 expression
     inhibition oligonucleotide
ΙT
     Immunosuppressants
     Transcription, genetic
        (T-lymphocyte gene CD28 expression inhibition by oligonucleotides
        contg. guanine quartet and treatment of immune system-mediated
        diseases)
IT
    Immunity
        (disease; T-lymphocyte gene CD28 expression inhibition by
        oligonucleotides contg. guanine quartet and treatment of immune
        system-mediated diseases)
ΙT
    Genetic vectors
        (expression; T-lymphocyte gene CD28 expression inhibition by
        oligonucleotides contg. guanine quartet and treatment of immune
        system-mediated diseases)
IT
    Gene, animal
     RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
        (CD28, T-lymphocyte gene CD28 expression inhibition by oligonucleotides
        contg. quanine quartet and treatment of immune system-mediated
```

diseases)

IT Antigens

RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)

(CD28, T-lymphocyte gene CD28 expression inhibition by oligonucleotides contg. guanine quartet and treatment of immune system-mediated diseases)

IT Lymphocyte

(T-cell, T-lymphocyte gene CD28 expression inhibition by oligonucleotides contg. guanine quartet and treatment of immune system-mediated diseases)

IT Nucleotides, biological studies

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oligo-, deoxyribo-, GGGG-contg.; T-lymphocyte gene CD28 expression inhibition by oligonucleotides contg. guanine quartet and treatment of immune system-mediated diseases)

IT Nucleotides

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oligo-, deoxyribo-, thiophosphate-linked, GGGG-contg.; T-lymphocyte gene CD28 expression inhibition by oligonucleotides contg. guanine quartet and treatment of immune system-mediated diseases)

IT 73-40-5DP, Guanine, quartet

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(T-lymphocyte gene CD28 expression inhibition by oligonucleotides

contg. guanine quartet and treatment of immune system-mediated diseases)

IT 181722-90-7P 181722-91-8P 181722-92-9P 181722-93-0P 181722-94-1DP, oligonucleotide derivs. 181722-95-2P 181722-96-3P RL: BAC (Biological activity or effector, except adverse); BPN

(Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)
(gene CD28 expression-inhibiting; T-lymphocyte gene CD28 expression
inhibition by oligonucleotides contg. guanine quartet and treatment of
immune system-mediated diseases)